// App-Quantinova.ai

321 : Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.

Researchers

Presenter

  • Luis Villanueva

Principal Investigators

  • Hyun Cheol Chung

  • Carlos Gomez-Roca

  • Federico Longo

  • Eduardo Yanez

  • Helene Senellart

  • Mark Doherty

  • Javier Garca-Corbacho

  • Andrew Eugene Hendifar

  • Corinne Maurice-Dror

  • Sanjeev Singh Gill

  • Tae Won Kim

  • Daniel Heudobler

  • Nicolas Penel

  • Razi Ghori

  • Peter Kubiak

  • Fan Jin

  • Kevin Glen Norwood

  • Donna Graham

Medical Centers

  • Fundación Arturo López Pérez, Providencia, Chile

  • Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, Australia

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • Institut Claudius Regaud, Toulouse, France

  • Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain

  • Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine,Universidad de la Frontera,Temuco,Chili

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada

  • Hospital Clinic de Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumours Lab (IDIBAPS), Barcelona, Spain

  • Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA

  • The Rappaport Faculty of Medicine, Technion, Haifa, Israel

  • The Alfred Hospital, Melbourne, Australia

  • Asan Medical Center, Seoul, South Korea

  • University of Regensburg, Regensburg, Germany

  • Centre Oscar Lambret, Lille, France

  • Merck & Co., Inc., Kenilworth, NJ

  • Eisai Inc, Woodcliff Lake, NJ

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

Locations

  • Chile

  • Australia

  • Republic of South Korea

  • France

  • Spain

  • Canada

  • United States

  • Israel

  • Germany

  • United Kingdom

Companies

  • Merck & Co., Inc.

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

Phase

  • II

Study Id's

  • NCT03797326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved